

# Galatea kallergi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2310719/publications.pdf>

Version: 2024-02-01

45  
papers

2,448  
citations

257450

24  
h-index

254184

43  
g-index

46  
all docs

46  
docs citations

46  
times ranked

3029  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelial-to-mesenchymal transition of tumor cells: cancer progression and metastasis. <i>International Journal of Developmental Biology</i> , 2022, 66, 277-283.	0.6	9
2	Detyrosinated $\beta$ -Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 154.	2.5	7
3	PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients's CTCs. <i>Cancers</i> , 2022, 14, 1731.	3.7	7
4	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. <i>Cancers</i> , 2022, 14, 1574.	3.7	8
5	Abstract 1119: Non-adherent breast and non-small-cell lung cancer cell cultures as a promising CTCs model for evaluation of the anti-tumor effects of artesunate. <i>Cancer Research</i> , 2022, 82, 1119-1119.	0.9	0
6	Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(+) breast cancer receiving salvage treatment with everolimus/exemestane. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 277-287.	2.3	5
7	Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. <i>Scientific Reports</i> , 2021, 11, 2313.	3.3	32
8	Clinical Relevance of Mesenchymal- and Stem-Associated Phenotypes in Circulating Tumor Cells Isolated from Lung Cancer Patients. <i>Cancers</i> , 2021, 13, 2158.	3.7	18
9	A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1395-1405.	3.2	12
10	Circulating tumor cells as prognostic biomarkers in breast cancer: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 1037-1048.	3.1	7
11	CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989575.	3.2	10
12	The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility. <i>Cancer Biology and Therapy</i> , 2020, 21, 533-540.	3.4	8
13	The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization. <i>Breast Cancer Research</i> , 2019, 21, 86.	5.0	21
14	CD8 <sup>+</sup> PD-1 <sup>+</sup> T-cells and PD-L1 <sup>+</sup> circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	3.2	13
15	The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 587-597.	4.1	23
16	Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775012.	3.2	61
17	Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes. <i>Molecular Oncology</i> , 2018, 12, 21-32.	4.6	13
18	Evaluation of $\beta$ -tubulin, detyrosinated $\beta$ -tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements. <i>Breast Cancer Research</i> , 2018, 20, 67.	5.0	25

#	ARTICLE	IF	CITATIONS
19	Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 1366-1376.	1.6	10
20	A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 594-606.	1.6	38
21	Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. <i>PLoS ONE</i> , 2017, 12, e0181211.	2.5	30
22	Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. <i>Oncotarget</i> , 2017, 8, 5309-5322.	1.8	30
23	Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs). <i>Cellular Physiology and Biochemistry</i> , 2016, 40, 411-419.	1.6	50
24	Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2015, 17, 113.	5.0	24
25	Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0123683.	2.5	49
26	Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. <i>Breast Cancer Research</i> , 2014, 16, 485.	5.0	51
27	Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. <i>BMC Cancer</i> , 2014, 14, 651.	2.6	97
28	Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 685-693.	2.3	32
29	Breast Cancer Metastasis Suppressor-1 Promoter Methylation in Primary Breast Tumors and Corresponding Circulating Tumor Cells. <i>Molecular Cancer Research</i> , 2013, 11, 1248-1257.	3.4	54
30	Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1886-1895.	4.1	96
31	Evaluation of proliferation and apoptosis markers in circulating tumor cells (CTCs) of women with early breast cancer who are candidates for tumor dormancy.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22101-e22101.	1.6	0
32	A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating HER2-positive tumor cells circulating in peripheral blood of women with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22105-e22105.	1.6	0
33	Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. <i>Annals of Oncology</i> , 2012, 23, 1744-1750.	1.2	133
34	Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2011, 13, R59.	5.0	327
35	Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. <i>Breast Cancer Research</i> , 2011, 13, R60.	5.0	74
36	Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. <i>Cancer Letters</i> , 2010, 288, 99-106.	7.2	269

#	ARTICLE	IF	CITATIONS
37	Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. <i>Cancer Biology and Therapy</i> , 2009, 8, 1470-1477.	3.4	46
38	Membrane androgen receptor activation in prostate and breast tumor cells: Molecular signaling and clinical impact. <i>IUBMB Life</i> , 2009, 61, 56-61.	3.4	57
39	Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 525-534.	2.5	44
40	Hypoxia-inducible factor-1 $\alpha$ and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2009, 11, R84.	5.0	111
41	Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. <i>Breast Cancer Research</i> , 2008, 10, R80.	5.0	128
42	Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 2593-2600.	7.0	220
43	Activation of FAK/PI3K/Rac1 Signaling Controls Actin Reorganization and Inhibits Cell Motility in Human Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2007, 20, 977-986.	1.6	93
44	Phosphorylation of FAK, PI-3K, and Impaired Actin Organization in CK-positive Micrometastatic Breast Cancer Cells. <i>Molecular Medicine</i> , 2007, 13, 79-88.	4.4	80
45	Distinct signaling pathways regulate differential opioid effects on actin cytoskeleton in malignant MCF7 and nonmalignant MCF12A human breast epithelial cells. <i>Experimental Cell Research</i> , 2003, 288, 94-109.	2.6	25